Home > Technology & Engineering > Biochemical engineering > Biotechnology > New Cardiovascular Research: PCSK9 as a New Therapeutic Target for Cardiovascular Disease
18%
New Cardiovascular Research: PCSK9 as a New Therapeutic Target for Cardiovascular Disease

New Cardiovascular Research: PCSK9 as a New Therapeutic Target for Cardiovascular Disease

          
5
4
3
2
1

Out of Stock


Premium quality
Premium quality
Bookswagon upholds the quality by delivering untarnished books. Quality, services and satisfaction are everything for us!
Easy Return
Easy return
Not satisfied with this product! Keep it in original condition and packaging to avail easy return policy.
Certified product
Certified product
First impression is the last impression! Address the book’s certification page, ISBN, publisher’s name, copyright page and print quality.
Secure Checkout
Secure checkout
Security at its finest! Login, browse, purchase and pay, every step is safe and secured.
Money back guarantee
Money-back guarantee:
It’s all about customers! For any kind of bad experience with the product, get your actual amount back after returning the product.
On time delivery
On-time delivery
At your doorstep on time! Get this book delivered without any delay.
Notify me when this book is in stock
Add to Wishlist

About the Book

Cardiovascular disease (CVD) is one of the major diseases which causing premature death in the world. Plasma LDL level is a major determinant of CVD. Statin drugs prove to be big success on reducing 30-40% cholesterol in some people, yet fail far short in others with initial high value of cholesterol. they need 2 or even 3 different drugs to reach the level Recent genetic studies have shown, one of the key genes, Proprotein convertase subtilisin/kexin type 9(PCSK9), plays a critical role in cholesterol metabolism by controlling the level of low-density lipoprotein receptor (LDLr). In the chapter I, introduction, we explain why study PCSK9 is important to human health. In chapter II . we described a high throughput assay to identify leading inhibitor compound for PCSK9..In the Chapter III, we describe a shotgun proteomic analysis of potential binding partners of PCSK9, some of them such as E38 ubiquitin ligase c-IAP1 could be significant modulators of PCSK9 function. In chapter IV, we discussed the possible role of the PCSK9 in the infectious disease. In Chapter V, we gave the latest progress using PCSK9 inhibitors, including using anti-PCSK9 antibody and anti/PCSK9 SiRNA to treat cardiovascular diseases. The best example of the SiRNA inhibition of PCSK9 is the drug, called Inclisiran, developed by the drug company Novartis. The drug can be administrated by injection twice a year to reduce the cholesterol level by 50%, which is already proved by the UK drug agency NICE. In Chapter VI, we discussed the possibility colchicine, PCSK9 and infection disease in TNF-alpha-mediated cytokine storm in COVID-19.


Best Sellers



Product Details
  • ISBN-13: 9798533140058
  • Publisher: Independently Published
  • Publisher Imprint: Independently Published
  • Height: 279 mm
  • No of Pages: 136
  • Spine Width: 7 mm
  • Weight: 335 gr
  • ISBN-10: 8533140053
  • Publisher Date: 22 Jul 2021
  • Binding: Paperback
  • Language: English
  • Returnable: N
  • Sub Title: PCSK9 as a New Therapeutic Target for Cardiovascular Disease
  • Width: 216 mm


Similar Products

How would you rate your experience shopping for books on Bookswagon?

Add Photo
Add Photo

Customer Reviews

REVIEWS           
Click Here To Be The First to Review this Product
New Cardiovascular Research: PCSK9 as a New Therapeutic Target for Cardiovascular Disease
Independently Published -
New Cardiovascular Research: PCSK9 as a New Therapeutic Target for Cardiovascular Disease
Writing guidlines
We want to publish your review, so please:
  • keep your review on the product. Review's that defame author's character will be rejected.
  • Keep your review focused on the product.
  • Avoid writing about customer service. contact us instead if you have issue requiring immediate attention.
  • Refrain from mentioning competitors or the specific price you paid for the product.
  • Do not include any personally identifiable information, such as full names.

New Cardiovascular Research: PCSK9 as a New Therapeutic Target for Cardiovascular Disease

Required fields are marked with *

Review Title*
Review
    Add Photo Add up to 6 photos
    Would you recommend this product to a friend?
    Tag this Book
    Read more
    Does your review contain spoilers?
    What type of reader best describes you?
    I agree to the terms & conditions
    You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.

    CUSTOMER RATINGS AND REVIEWS AND QUESTIONS AND ANSWERS TERMS OF USE

    These Terms of Use govern your conduct associated with the Customer Ratings and Reviews and/or Questions and Answers service offered by Bookswagon (the "CRR Service").


    By submitting any content to Bookswagon, you guarantee that:
    • You are the sole author and owner of the intellectual property rights in the content;
    • All "moral rights" that you may have in such content have been voluntarily waived by you;
    • All content that you post is accurate;
    • You are at least 13 years old;
    • Use of the content you supply does not violate these Terms of Use and will not cause injury to any person or entity.
    You further agree that you may not submit any content:
    • That is known by you to be false, inaccurate or misleading;
    • That infringes any third party's copyright, patent, trademark, trade secret or other proprietary rights or rights of publicity or privacy;
    • That violates any law, statute, ordinance or regulation (including, but not limited to, those governing, consumer protection, unfair competition, anti-discrimination or false advertising);
    • That is, or may reasonably be considered to be, defamatory, libelous, hateful, racially or religiously biased or offensive, unlawfully threatening or unlawfully harassing to any individual, partnership or corporation;
    • For which you were compensated or granted any consideration by any unapproved third party;
    • That includes any information that references other websites, addresses, email addresses, contact information or phone numbers;
    • That contains any computer viruses, worms or other potentially damaging computer programs or files.
    You agree to indemnify and hold Bookswagon (and its officers, directors, agents, subsidiaries, joint ventures, employees and third-party service providers, including but not limited to Bazaarvoice, Inc.), harmless from all claims, demands, and damages (actual and consequential) of every kind and nature, known and unknown including reasonable attorneys' fees, arising out of a breach of your representations and warranties set forth above, or your violation of any law or the rights of a third party.


    For any content that you submit, you grant Bookswagon a perpetual, irrevocable, royalty-free, transferable right and license to use, copy, modify, delete in its entirety, adapt, publish, translate, create derivative works from and/or sell, transfer, and/or distribute such content and/or incorporate such content into any form, medium or technology throughout the world without compensation to you. Additionally,  Bookswagon may transfer or share any personal information that you submit with its third-party service providers, including but not limited to Bazaarvoice, Inc. in accordance with  Privacy Policy


    All content that you submit may be used at Bookswagon's sole discretion. Bookswagon reserves the right to change, condense, withhold publication, remove or delete any content on Bookswagon's website that Bookswagon deems, in its sole discretion, to violate the content guidelines or any other provision of these Terms of Use.  Bookswagon does not guarantee that you will have any recourse through Bookswagon to edit or delete any content you have submitted. Ratings and written comments are generally posted within two to four business days. However, Bookswagon reserves the right to remove or to refuse to post any submission to the extent authorized by law. You acknowledge that you, not Bookswagon, are responsible for the contents of your submission. None of the content that you submit shall be subject to any obligation of confidence on the part of Bookswagon, its agents, subsidiaries, affiliates, partners or third party service providers (including but not limited to Bazaarvoice, Inc.)and their respective directors, officers and employees.

    Accept

    New Arrivals



    Inspired by your browsing history


    Your review has been submitted!

    You've already reviewed this product!